# Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

> **NCT04863014** · PHASE2 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 21 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** evinacumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04863014
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-07-12
- **Primary completion:** 2023-02-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04863014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04863014, "Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04863014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*